Results 291 to 300 of about 44,321 (338)

Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Atham Ali, Alvin Phan, Vijaya Vaikari, Mincheol Park, Mateusz Pospiech, Ryan Chu, Yiting Meng, J. Andrew MacKay, Houda Alachkar   +8 more
openalex   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Supplementary Table S4 from Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, Sina Nassiri, Sabrina Danilin, Emily Piccione, Emilio Yángüez, Tamara Hüsser, Sylvia Herter, Stephan Schmeing, Petra Gerber, Petra Schwalie, Johannes Sam, Stefanie Briner, Sylvia Jenni, Roberta Bianchi, Marlene Biehl, Floriana Cremasco, Katerina Apostolopoulou, Hélène Haegel, Christian Klein, Pablo Umaña, Marina Bacac   +22 more
openalex   +1 more source

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein. [PDF]

Proc Natl Acad Sci U S A
Radić L, Offersgaard A, Kadavá T, Zon I, Capella-Pujol J, Mulder F, Koekkoek S, Spek V, Chumbe A, Bukh J, van Gils MJ, Sanders RW, Yin VC, Heck AJR, Gottwein JM, Sliepen K, Schinkel J.   +16 more
europepmc   +1 more source

Data from IMiDs augment CD3-bispecific antibody induced CD8+ cell cytotoxicity and expansion by enhancing IL-2 production

Ji Li, Dionysos Slaga, Jennifer Johnston, Teemu T. Junttila   +3 more
openalex   +1 more source

Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials. [PDF]

Cureus
Khan AA, Rahman M, Jawed I, Sajjad M, Khan MM.   +4 more
europepmc   +1 more source

Data from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu   +15 more
openalex   +1 more source

Characterization of <i>O</i>-Glycosylation and <i>N</i>-Glycosylation in Bispecific Antibodies and Its Importance in Therapeutic Antibody Development. [PDF]

Pharmaceuticals (Basel)
Duan M, Guo L, Long Z, Ni Y, Yang Y, Du J, Li M, Zhang J, Tang T, Yu C, Wang L.   +10 more
europepmc   +1 more source

First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report

Haishuang Sun, Yang Liu, Zihong Chen, Wenfeng Fang, Li Zhang, Yaxiong Zhang   +5 more
openalex   +1 more source